Baptist Health breaks ground on Pembroke Pines facility
Story Highlights Baptist Health South Florida breaks ground on 60,865-square-foot facility in Pembroke Pines.
Facility will house emergency, brain, heart, and primary care services.
Baptist Health acquired the 4.74-acre site for $13.2 million in 2024.
Baptist Health South Florida broke ground on an emergency medicine/outpatient care facility in Pembroke Pines that will host more than 100 employees.
Located at 1400 S.W. 145th Ave., the project will total 60,865 square feet in three stories. The Miami-based nonprofit will house a free-standing emergency department, brain and spine care, heart and vascular care, and primary care offices. It should open in early 2027.
GET TO KNOW YOUR CITY
Find Local Events Near You
Connect with a community of local professionals.
Explore All Events
'This groundbreaking marks more than the start of construction—it's a commitment to advancing healthcare in a way that truly centers around the community,' said Nancy Batista-Rodriguez, CEO of Baptist Outpatient Services. 'We're building not just a structure, but a place where people can come for expert care, trusted guidance, and long-term wellness support.'
Miami-based Vilar Hoynack Construction is the general contractor.
Baptist Health acquired the 4.74-acre site for $13.2 million in 2024. It's near the Shops of Pembroke Gardens open-air mall and just off the Pines Boulevard exit of Interstate 75.
'The communities we serve are growing rapidly, and so are their healthcare needs,' said Dr. Jack Ziffer, executive VP and chief clinical officer of Baptist Health. 'This new medical center will allow us to expand our reach and provide the kind of coordinated, high-quality care our patients deserve—right in their own neighborhood.'
Baptist Health has been expanding its outpatient centers and free-standing emergency departments across South Florida in recent years as it seeks to reach more patients. It's particularly active in Broward County, as Baptist Health has secured property in Sunrise for its first hospital in Broward.
Sign up here for the Business Journal's free morning and afternoon daily newsletters to receive the latest business news impacting South Florida. Download the free Business Journal app for breaking news alerts on your phone.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
8 hours ago
- Chicago Tribune
Funding cuts ripple across Northwestern, as faculty urge no deal with Trump
Nearly four months have passed since the Donald Trump administration abruptly froze $790 million in federal funding at Northwestern University, and the school's fragile research infrastructure has been pummeled by cuts. Portions of research and clinical trials have ground to a halt. Labs have been instructed to scrutinize every expense, from equipment to personnel. Some teams are even killing off lab mice because it's cheaper than feeding them and cleaning cages. With university President Michael Schill set to appear again before a congressional committee Tuesday, rumors of a possible deal with the White House have gripped campus. But the situation on-the-ground remains dire, according to faculty and staff. 'Let's say they unfreeze the funds. The damage is done,' said Guillermo Oliver, a professor in the Division of Nephrology and Hypertension. 'Let's be clear, this is not going to be, 'OK, back to business.'' Northwestern never received formal notification of the funding freeze in April, which came amid several federal probes into allegations of antisemitism. The Evanston-based university has been spending about $10 million a week to keep research afloat, faculty told the Tribune in June. That's led officials to pursue a string of belt-tightening measures. Last week, the university eliminated more than 400 positions, half of which were already vacant. A month earlier, officials announced changes to employees' health insurance plans and a hiring freeze. While Northwestern pays out-of-pocket for research, departments have urged scientists to crimp spending. The Feinberg School of Medicine, which receives 70% of the university's research funding, has seen the brunt of those cuts — potentially putting lifesaving work at risk, faculty say. The Oliver Lab at Feinberg studies the biological development of the lymphatic system. Each piecemeal reduction has contributed to an environment of uncertainty among its staff. As the freeze drags on, Oliver isn't sure how long he can maintain bare-bones operations. 'We were asked to cut as many costs as we could, in everything,' Oliver said. 'The stressful question is, 'When will this be over?' We have no idea.' Many Northwestern scientists, including Oliver, utilize genetically engineered mice specifically bred for lab work. But animal costs have had to be reduced, too. 'It was not mandatory,' he said. 'Nobody told us, 'You need to reduce your mouse colony by 50%.' Rather it was, 'Try to reduce as much as you can without major impact to your research.'' Infrastructure for labs and clinical trials takes time to develop, and sudden shifts in resources and personnel can jeopardize years of work. That can't be immediately reversed, researchers say. Scott Budinger, chief of pulmonary and critical care in the department of medicine, has spent more than two decades researching drugs to treat pneumonia. While his team is still able to collect vital patient samples, they've been left untouched in a freezer. 'The work on those new drug targets has virtually stopped … All of that work could be gone in several months,' Budinger said. 'If we start to lose the people and lose the expertise, you can't just step in and rebuild that work.' It's unclear how much longer Northwestern can continue to fund research without reimbursement. A university spokesperson did not respond to requests for comment. Northwestern is among the wealthiest universities in the country, with a $14.3 billion endowment. But the school's business model was built on grants: During its 2023-24 fiscal year, it received $1.05 billion in research funding. Amid the pause, the endowment and donors can only offer so much support. Endowments weren't designed to be rainy-day funds or sitting cash. A large portion of the capital is invested in hedge funds and private equity. Much of the pool is also restricted, meaning the funds are reserved by donors for specific purposes — such as scholarships or academic programs. In a typical year, most universities only draw from their year-to-year earnings at a rate of less than 5% of the total endowment. That uncertainty — coupled with perceived threats to academic freedom — has led some scientists to explore opportunities elsewhere, even outside of the U.S. Faculty members have voiced concerns that a potential exodus of researchers could undermine Northwestern's competitiveness on the global stage. It's an option weighed by Benjamin Thomson, an assistant professor of ophthalmology who said he would consider returning to his home country of Canada. 'I've done some looking at positions,' Thomson said. 'I have no immediate intention of leaving, but it's not something I would necessarily be averse to if the situation were different.' In recent weeks, several Ivy League schools have settled with the Trump administration to restore paused funding. Columbia University, for example, will pay more than $220 million to the federal government and implement several initiatives aimed at addressing antisemitism on campus. The Wall Street Journal reported that Northwestern officials were also in talks with White House. A university spokesperson declined to comment, but rumors of a deal have already rippled through campus. Northwestern's Concerned Faculty Group, which represents hundreds of members, said in a statement last week that a settlement would make the school 'complicit in an assault on institutions of higher education.' The Trump administration has leveraged federal funding to force universities to comply with its agenda, the statement said. 'This is extortion,' said Laura Beth Nielsen, a professor of sociology and member of the group. 'We need to resolve the situation, but not at the expense of academic freedom.' Meanwhile, Schill is set to appear again before the House Committee on Education and the Workforce in a transcribed interview closed to the press Tuesday. When he last appeared before the Republican-led body in May 2024, he was grilled for hours about the campus environment for Jewish students. A committee spokesperson did not directly comment on when or if the transcription might be made public. 'We all agree that if there is an antisemitism problem on campus, that the university is under an obligation to take action to stop it,' said Paul Gowder, a professor of law. 'But we also all agree that this is a pretext.' The situation has left some faculty conflicted. Many are alarmed by the prospect of yielding to federal pressure, but also recognize that an indefinite funding freeze poses serious risks. Melissa Simon, vice chair for research in the department of general obstetrics and gynecology, was one of the highest-funded Northwestern professors through the National Institutes of Health. In May, her research hub, the Center for Health Equity Transformation, was shuttered with just minutes' notice. Simon suspects Northwestern closed the lab to comply with the Trump administration's crackdown on diversity, equity and inclusion initiatives. A few weeks later, she was allowed to resume the center's research under a new name, Elevate Lab. But the whiplash has been draining. 'I'm fighting every day. It has been demoralizing and exhausting,' Simon said. 'But how much will so-called negotiation with Trump help?' Last week, Simon was forced to lay off her program assistant, Chisom Chima, her only staffer not funded by grant money. Both women were devastated. 'It's very heartbreaking, not just to lose a job, but to lose a job working with this team,' Chima said. 'Everyone has been on edge.' Next month, undergraduate students will begin to trickle back to campus. It won't be a typical academic year. When Schill announced the layoffs last week, he called the period of the freeze 'among the most difficult in our institution's 174-year history.' But the message among faculty is clear: The university is at a tipping point for research. 'I think if the freeze were reversed today, we could get things back,' Budinger said. 'I don't think it's too late yet, but time is running out.'
Yahoo
9 hours ago
- Yahoo
American Alcohol-Free Association Celebrates 5 Years of Promoting Sobriety and Healthier Lifestyles
In 2023, 12,429 People Died in Alcohol-Impaired Driving Crashes Miami, Florida--(Newsfile Corp. - August 4, 2025) - Founded in 2020 by visionary entrepreneur Reynald Vito Grattagliano, the American Alcohol-Free Association (AAFSA) proudly celebrates five years of empowering people to live sober and healthier lives. Supported by Arkay Beverages and Beyond Spirits, AAFSA has become a leading voice in the alcohol-free and zero-proof movement across the United States and beyond. AAFSA Created in response to the growing demand for health-conscious and alcohol-free alternatives, AAFSA serves as a community platform for both consumers and brands who believe in the benefits of sobriety. "When we launched AAFSA in 2020, our mission was to inspire people to enjoy life without alcohol," said Reynald Vito Grattagliano, President and Founder of AAFSA. "Five years later, we are proud to see a growing community embracing zero-proof options, enjoying social moments without compromise, and making healthier lifestyle choices." The Life-Saving Impact of Sobriety Alcohol consumption continues to pose a major public health risk in the United States: Drunk driving kills 34 people every day-that's one person every 42 minutes. In 2023 alone, 12,429 lives were lost in alcohol-impaired driving crashes. (Source: NHTSA) About 20,000 U.S. adults die each year from alcohol-associated cancers, most of which could have been prevented by following recommended drinking limits. (Source: CDC) These tragic and preventable losses destroy families and communities. Behind every statistic is a family grieving a loved one. Reynald Vito Grattagliano An Invitation to Beverage Makers: Join Forces for a Happier World The American Alcohol-Free Association is calling on all beverage makers-alcohol-free producers, soda brands, and spirits companies-to join forces to prevent this ongoing tragedy. "We want a happier world, and we want happy families-not families destroyed by the loss of their loved ones to alcohol-related tragedies," said Grattagliano. "Together, we can create a cultural shift where choosing alcohol-free options becomes the norm and where enjoyment never comes at the cost of a life." Join the Movement AAFSA invites leading alcohol-free and zero-proof brands to unite their efforts and accelerate the shift toward sobriety. Consumers and supporters are encouraged to join the association and access exclusive resources at With the continuous rise of mocktails, alcohol-free spirits, and wellness-oriented socializing, the American Alcohol-Free Association is shaping the future of responsible enjoyment-where sobriety is a celebration, not a limitation. Press Contact: Person Name: Reynald Vito GrattaglianoCompany Name:Alcohol-Free AssociationEmail: info@ To view the source version of this press release, please visit
Miami Herald
9 hours ago
- Miami Herald
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency - FDA decision expected in 2H'2025 - Access the "What This Means" segment here IRVINE, CA / ACCESS Newswire / August 4, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a Virtual Investor "What This Means" segment entitled, "enVVeno Medical - Making Veins Work Again - How President Trump's CVI Diagnosis is Raising Awareness." Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discussed the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval. The Company estimates that there are approximately 2.5 million patients in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025. The "What This Means" segment can be accessed here. About CVI Severe deep venous CVI is a serious and debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments that repair deep venous valve dysfunction, the #1 cause of severe CVI-a disease estimated to cost the U.S. healthcare system in excess of $26 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. INVESTOR CONTACT: Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation
